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H I G H L I G H T S
• Two compound heterozygote patients for LPL mutations have a severe phenotype.
• Both patients have very low levels of circulating LPL and it is not active.
• LPL V200A, in vitro, is markedly less secreted and not enzymatically active.
• LPL N291S, in vitro, is secreted but not enzymatically active.
• V200A and N291S mutations do not aﬀect LPL dimerization.
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Background and aims: Type I hyperlipoproteinemia is an autosomal recessive disorder of lipoprotein metabolism
caused by mutations in the LPL gene, with an estimated prevalence in the general population of 1 in a million. In
this work, we studied the molecular mechanism of two known mutations in the LPL gene in ex vivo and in vitro
experiments and also the eﬀect of two splice site mutations in ex vivo experiments.
Methods: Two patients with hypertriglyceridemia were selected from the Lipid Clinic in Vienna. The ﬁrst patient
was compound heterozygote for c.680T > C (exon 5; p.V200A) and c.1139+1G > A (intron 7 splice site). The
second patient was compound heterozygote for c.953A > G (exon 6; p.N291S) and c.1019-3C > A (intron 6
splice site).
The LPL gene was sequenced and post-heparin plasma samples (ex vivo) were used to test LPL activity. In vitro
experiments were performed in HEK 293T/17 cells transiently transfected with wild type or mutant LPL plas-
mids. Cell lysate and media were used to evaluate LPL production, secretion, activity and dimerization by
Western blot analysis and LPL enzymatic assay, respectively.
Results: Our data show that in both patients, LPL activity is absent. V200A is a mutation that alters LPL secretion
and activity whereas the N291S mutation aﬀects LPL activity, but both mutations do not aﬀect dimerization. The
eﬀect of these mutations in patients is more severe since they have splice site mutations on the other allele.
Conclusions: We characterized these LPL mutations at the molecular level showing that are pathogenic.
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1. Introduction
Lipoprotein lipase (LPL) is a key enzyme in triglycerides (TGs)
catabolism, whose role is to catalyze the hydrolysis of TGs in TG-rich
lipoproteins such as chylomicrons and VLDL [1]. LPL belongs to the
mammalian lipase family that includes hepatic lipase, gastric lipase,
pancreatic lipase and endothelial lipase [2]. Human LPL gene is located
on chromosome 8p22, spans 30 kb and is divided into 10 exons [3]
encoding for a secreted protein of 448 amino acids and a 27-amino-acid
signal peptide. LPL is primarily synthesized in adipocytes, macro-
phages, muscle cells where the dimer formation is the key step for LPL
activity. It is transported to the luminal surface of vascular endothelial
cells [4]. Indeed, the enzymatically active dimers of LPL hydrolyze
triglycerides of chylomicrons and VLDL, releasing free fatty acids [5].
Intravenous administration of heparin displaces LPL into circulation,
allowing the study of genotype/phenotype relation by measurement of
LPL activity and mass in post-heparin plasma [6]. More than 200
naturally occurring mutation in the LPL gene have been identiﬁed
[7,8]. They are located in the promoter region, the coding exons,
mainly exon 5 and 6 [9], or splice junction sites and aﬀect LPL activity
by interfering with secretion, heparin binding or enzymatic activity
[10]. Among these, the loss of function mutations leads to the onset of
type I hyperlipoproteinemia, also known as familial lipoprotein lipase
deﬁciency or familial chylomicronemia syndrome (FCS), characterized
by impaired TGs hydrolysis that causes accumulation of chylomicrons
and extremely high levels of triglycerides in the plasma (880mg/dL or
10mmol/L) [11]. Main symptoms of type I hyperlipoproteinemia in-
clude severe abdominal pain such as repetitive colicky pain, hepatos-
plenomegaly, the hyperviscosity syndrome, eruptive xanthomas and
lipaemia retinalis. However, the most debilitating symptom is the re-
currence of severe potentially life-threatening acute pancreatitis attacks
(PAs) occurring in 30% of patients [12].
Since TG-lowering drugs, such as niacin and ﬁbrates, are not ef-
fective in patients with type I hyperlipoproteinemia, the main ther-
apeutic approach consists of diet treatment to reduce TGs levels, which
usually has poor compliance [13,14]. Acute plasmapheresis may help
during an episode of acute pancreatitis, but there is a lack of proven
evidence through randomized controlled trials [15–17]. Furthermore,
for the treatment of adults with genetically conﬁrmed type I hyperli-
poproteinemia and with an LPL protein mass> 5% of normal, who
suﬀer from severe/multiple pancreatitis attacks, the ﬁrst gene therapy
treatment has been approved by the European Medicines Agency [18].
Speciﬁcally, Alipogene tiparvovec (Glybera®) gene therapy is an adeno-
associated virus (AAV) serotype 1 (AAV-1) based that results in sus-
tained expression of the naturally occurring, gain-of-function S447X
variant of the human LPL gene and subsequent synthesis and secretion
of active LPL by the muscle cells [17,19]. Of note, the Glybera (alipo-
gene tiparvovec) gene therapy, already approved in Europe, is being
withdrawn not due to risk-beneﬁt but relative to cost-eﬀectiveness, i.e.
an average of $1 million per treatment [20].
The present study was aimed to fully characterize two known mis-
sense mutations (p.V200A and p.N291S) in the LPL gene by ex vivo and
in vitro experiments and tested the additional eﬀect of two splice site
mutations by ex vivo experiments. The splice site mutation c.1019-
3C > A (intron 6) has been previously described [21], while the
c.1139+1G > A (intron 7) has been described for the ﬁrst time in this
work. We found that the mutations are pathogenic.
2. Materials and methods
2.1. Subjects
Between April 2016 and April 2017, two patients from the Lipid
Clinic in Vienna (Austria) with excessive primary hypertriglyceridemia
with no other apparent cause were analyzed in more details during
clinical workup since they were not carriers of well characterized LPL
mutations. Routine clinical determination of serum lipid levels was
performed by enzymatic methods (Roche reagents, run on a Cobas C111
analyzer) assessed as previously described [22]. Chylomicrons were
analyzed by ﬂoating in microliter tubes for 10min at 16.000 g (max-
imal) at 4°C prior to triglyceride determinations. Chylomicron trigly-
ceride concentrations were determined by subtracting the cleared in-
franatant from original serum.
2.2. DNA sequencing
For massive-parallel sequencing, genes linked to hyperlipidemias
were enriched from isolated genomic DNA using a customized gene
panel (Nextera Rapid Capture Custom Enrichment; Illumina, San Diego,
CA) and sequenced on a MiSeq sequencing platform (Illumina, USA)
using 2× 150-bp paired-end chemistry in accordance with manu-
facturer instructions. Sequenced reads were aligned to the GRCh37/
hg19 human reference. Data analysis including copy number variation
(CNV) analysis was performed with the SeqNext® software (JSI Medical
Systems GmbH, Germany). The region of interest was the coding re-
gion ± 30 bp intronic ﬂanking regions of the LPL gene
(NM_000237.2). The classiﬁcation of detected variants followed the
consensus recommendations of the American College of Medical
Genetics and Genomics and the Association for Molecular Pathology
[23]. In addition to LPL, also APOC2, APOA5, LMF1 and GPIHBP1 genes
have been sequenced, without ﬁnding any other mutation.
2.3. Post-heparin plasma samples collection
Post-heparin plasma was obtained as previously described [14].
Brieﬂy, pre-heparin blood sample was drawn at a fasting state followed
by an intravenous bolus injection of heparin (60 IU/kg body weight)
and collection of post-heparin blood 10min later from the contralateral
arm. Blood samples were centrifuged at 3000 rpm at 4 °C for 10min to
obtain plasma samples, and supernatants stored at −80 °C until ana-
lyzed.
2.4. Site-direct mutagenesis, cloning, and transfection
Wild type LPL cDNA was synthesized and cloned in pcDNA3.1
vector with a V5 epitope tag at the C-terminus by GeneArt Gene
Synthesis (Thermo Fisher Scientiﬁc, Rockford, IL) as previously de-
scribed [14].
To obtain the LPL V200A mutation, a single base-pair change from
valine to alanine at nucleotide 200 was introduced using in situ muta-
genesis technique (primer forward: CAG AAA CCA GCT GGG CAT GTT
and primer reverse: AAC ATG CCC AGC TGG TTT CTG). To obtain the
LPL N291S substitution (from asparagine to serine at nucleotide 291)
the following primers were used: primer forward GCT ATG AGA TCA
CTA AAG TCA GAG C, primer reverse GCT CTG ACT TTA CTG ATC TCA
TAG G. A detailed protocol for mutagenesis is available on request. All
the primers were purchased from Sigma Aldrich (St. Louis, MO) and the
presence of the LPL mutation and ﬁdelity of each construct were con-
ﬁrmed by DNA sequencing (Euroﬁns Genomic, Germany).
Human embryonic kidney 293T/17 (HEK 293T/17) cells from
American Tissue Culture Collection (Manassas, VA) were cultured in
high glucose Dulbecco's Modiﬁed Eagle's Medium containing 10% Fetal
Bovine Serum (FBS), 5% penicillin-streptomycin and 2mM L-glutamine
and transfected with plasmids containing the human wild type LPL
cDNA or carrying one of the other variants (3 mg/mL) as previously
described [13].
After 48 h cells were lysed using mammalian protein extraction
reagent (M-PER, ThermoFisher Scientiﬁc) containing complete protease
inhibitor cocktail (Sigma Aldrich) and media were concentrated 10
times by centrifuging using VIVASPIN tubes (Sartorius Stedim Biotech,
Göttingen, Germany). HEK 293T/17 lysates and media were used to
analyze protein synthesis and secretion by Western blot; media
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fractions were additionally used to measure LPL activity.
2.5. Immunoblotting
Post-heparin plasma samples were diluted 1:50 in 0.5-M Tris-HCl
(pH 7). The diluted plasma samples, cell lysates, and concentrated
media samples were mixed with Laemmli buﬀer 5X (SDS 10%, Tris HCl
62.5 mM pH 6.8, glycerol 50%, bromophenol blue 0.01% and β-mer-
captoethanol 25%) and boiled for 5min at 95 °C. Proteins were size-
separated by SDS-PAGE (10% acrylamide gel, SDS 0.1%, 100 V, 90min,
using running buﬀer containing 0.1% SDS) and transferred onto a ni-
trocellulose membrane (400mA, 60min). Membranes were incubated
for 1 h with primary antibodies, washed 2 times for 10min with 0.2%
tris-buﬀered saline containing 0.2% tween (TBST), incubated 1 h with
HRP-conjugated secondary antibodies, then washed 3 times for 10min
with TBST. Membranes were incubated for 5min with chemilumines-
cent HRP substrate (Millipore Corporation, Billerica, MA). Bands were
visualized by Chemidoc XRS System (Biorad, Hercules, CA) and quan-
tiﬁed using Image Lab Software (Biorad). The following antibodies
were used: mouse anti-LPL (Sigma-Aldrich) (1:1000), mouse anti-
APOA1 (AbD Serotec, Oxford, UK) (1:500), mouse anti-V5 (Invitrogen)
(1:5000), rabbit anti-Calnexin (Sigma-Aldrich) (1:2000), mouse anti-
Albumin (Sigma-Aldrich) (1:1000).
2.6. Lipoprotein lipase enzymatic activity
LPL enzymatic activity, in pre-heparin and post-heparin human
plasma samples and in media fractions of HEK293T/17 cells transfected
with LPL wild type plasmid and the two plasmids containing LPL mu-
tants, was measured as previously described [13,14]. Brieﬂy, 7.5 μL of
each plasma sample was mixed with 42.5 μL of 0.2-M Tris HCl buﬀer
(pH 8.0). The diluted plasma samples and 50 μL of each concentrated
medium sample were incubated for 15min at 37 °C with a reaction mix
containing radiolabeled substrate [9,10-3H(N)]-triolein (Perkin Elmer,
Waltman, MA), cold triolein and phosphatidylcholine (Sigma-Aldrich,
St Louis, MO), heat-inactivated FBS and bovine serum albumin (Sigma-
Aldrich, St Louis, MO) in presence or absence of 1M NaCl. The reaction
was stopped and lipids were extracted using a solution of heptane/
chloroform/methanol (1:1.25:1.41). Samples were then centrifuged at
3000 g for 15min and the amount of [3H]-oleic acid released was
analyzed by scintillation counting in the upper phase. A mouse (C57BL/
6) post-heparin plasma was used as a positive control, whereas 1M
NaCl was used for LPL speciﬁcity.
2.7. Analysis of LPL dimerization
Equal volumes of post-heparin plasma samples diluted 1:50 and
conditioned media were mixed with non-denaturing loading buﬀer 5X
(Tris HCl 62.5mM pH 6.8, glycerol 50%, bromophenol blue 0.01%, β-
mercaptoethanol 5% and Coomassie blue G250 0.05%). Samples were
not boiled. Proteins were separated by non-denaturing PAGE (4–15%
gradient acrylamide gel without SDS, 100 V, 90min), and transferred
onto a nitrocellulose membrane (400mA, 60min). Then, western
blotting was performed as described into immunoblotting section.
2.8. Homology modeling of LPL
The homology model of human LPL was created with the protein
fold recognition server Swiss-Model. The 3D structure of the human
pancreatic lipase-related protein 1 was selected as template. Calculated
models were visualized by Swiss PDB Viewer 4.1.0. LPL model was
mutated on the computer at position 200 by substituting valine (V), a
non-polar aliphatic residue, for alanine (A), another non-polar aliphatic
residue. The same procedure was applied to N291S mutation, sub-
stituting asparagine (N), an uncharged polar residue, at position 291 for
serine (S), another uncharged polar residue.
3. Results
3.1. Genetic screening
A 37-year-old normal-weight male patient (patient 1) of Indian
origin and non-consanguineous parents, whose father died for myo-
cardial infarction, was admitted to our metabolic clinic due to excessive
hypertriglyceridemia (see family tree in Fig. 1A). The history revealed
manifold bouts of pancreatitis and triglyceride levels> 2000mg/dL,
the last veriﬁed seven months ago. Alcohol consumption was denied,
xanthomas were not present at the time of investigation. Serum tri-
glyceride levels remained above 900mg/dL under low-fat and carbo-
hydrate-modiﬁed diet and the prescribed lipid lowering medication
(atorvastatin 40mg qd, fenoﬁbrate 200mg qd), but were reduced down
to 250mg/dL during pancreatitis attacks following prolonged fasting.
Comedication was limited to calcium and vitamin D 1200 IU qd Lipo-
protein ultracentrifugation revealed type I hyperlipoproteinemia with
triglycerides of 1162mg/dL, 635mg/dL from which in chylomicrons,
and cholesterol 223mg/dL. Testing for LPL mutations revealed two
Fig. 1. Pedigree of families.
(A) Family tree of patient 1 (II:1) carrying two heterozygous mutations:
c.680T > C (p.V200A) and c.1139+1G > A (intron 7 splice site). (B) Family
tree of patient 2 (III:2) carrying two heterozygous mutations: c.953A > G
(p.N291S) and c.1019-3C > A (intron 6 splice site). Only patient 1 and patient
2 have been genotyped in both families; open symbols indicate no known hy-
perlipidemia. The half-ﬁlled symbols are only by inference (but do not include
the possibility of a de novo mutation). Squares and circles represent male and
female family members, respectively, and ﬁlled symbols plus arrows denote
aﬀected individuals with LPL deﬁciency.
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heterozygous mutations c.680T > C (p.V200A) and c.1139+1G > A
(intron 7 splice site).
Patient 2 is a 40-year-old slightly overweight (BMI 27 kg/m2) male
of Caucasian origin and non-consanguineous parents (see family tree in
Fig. 1B). He had TG-levels of approximately 3500mg/dL, which were
ﬁrst discovered at 18 years of age and decreased to< 500mg/dL under
strict diet. He did not have a history of acute pancreatitis. His medi-
cation comprised bezaﬁbrate 400mg qd and vitamin D 2000 IU qd.
Genetic analysis of the LPL gene revealed two following heterozygous
mutations: c.953A > G (p.N291S) and c.1019-3C > A (intron 6 splice
site). In addition to LPL, in both patients, APOC2, APOA5, LMF1 and
GPIHBP1 have been sequenced without identifying pathogenic muta-
tions.
3.2. Circulating LPL levels and LPL activity in post-heparin plasma
Post-heparin plasma samples were collected from two patients, both
compound heterozygous for mutations in LPL gene, and used to analyze
circulating LPL levels and to measure LPL activity. Circulating LPL le-
vels were markedly low. In particular, in both post-heparin plasma
samples the LPL protein was detected as a very faint band compared to
the mouse post-heparin sample, which was used as positive control
(Fig. 2A). Post-heparin plasma samples were used also to test the en-
zymatic activity of LPL. In both blood samples, no release of [3H]-oleic
acid from triolein was detected, indicating that there was no LPL ac-
tivity (Fig. 2B).
3.3. LPL synthesis, secretion and activity in HEK293T/17 cells
To understand the molecular mechanism of these two mutations in
the LPL gene, wild type LPL cDNA was cloned into pcDNA3.1 expression
vector and the two mutants were obtained by in situ mutagenesis. To
ensure the speciﬁcity for LPL, at the C-terminus of the protein a V5 tag
was added. LPL V200A and N291S constructs were used to transiently
transfect HEK293T/17 cells which were harvested after 48 h; media
were collected and concentrated 10 times as previously described [14].
HEK293T/17 cells transfected with both mutant plasmids showed a
very slight decrease in protein production (about 10%), compared to
cells transfected with wild type LPL plasmid. However, no diﬀerences
were found in protein synthesis (Fig. 3A).
As a further step, the secretion of LPL in the medium fractions was
measured. In HEK293T/17 cells transfected with LPL V200A, LPL levels
in the medium were signiﬁcantly reduced by about 80% (p=0.008);
conversely, cells transfected with LPL N291S did not show any fall in
protein secretion (Fig. 3B). As a further step, LPL activity was evaluated
in concentrated media of cells transfected with wild type or mutant
plasmids were used. No LPL activity was detected in the media of cells
transfected with LPL V200A, while a strong reduction was found with
LPL N291S compared to LPL wild type (Fig. 4). Collectively, these data
show that the V200A substitution does not aﬀect protein synthesis but
induces a strong reduction in protein secretion and enzymatic activity.
On the other hand, N291S substitution strongly aﬀects the proper
functionality of LPL enzyme, despite it does not aﬀect protein synthesis
and secretion.
3.4. Analysis of LPL dimerization
To elucidate whether V200A and N291S mutations suppressed the
dimerization of LPL, post-heparin plasma and conditioned media were
analyzed by a non-denaturing gel Western blot. The results revealed
that both mutations exerted no inﬂuence on the LPL dimerization
(Fig. 5).
3.5. 3D structure of human LPL
The ﬁnal model of the LPL molecule, in ribbon format, is illustrated
in Fig. 6 by Swiss PDB Viewer. LPL is organized into two distinct
structural domains the amino terminal (residues 1–312) and the car-
boxy terminal (residues 313–448). The lid structure (residues 216–239)
covering the catalytic site is located in the N-domain. Since residue 200
and 291 are located in the coil region of loops, no changes were ob-
served in the backbone of the molecules compared with the wild type
LPL when the models were superimposed.
4. Discussion
Type I hyperlipoproteinemia is an autosomal recessive disorder of
lipoprotein metabolism caused by mutations in the LPL gene with an
estimated prevalence in general population of 1 in a million [24–26].
In this work, we studied the molecular mechanism of two known
mutations in LPL gene by ex vivo and in vitro experiments and also the
additional eﬀect of two splice site mutations by ex vivo experiments. We
described two patients carrying pathogenic mutations in the LPL gene:
patient 1 compound heterozygote for c.680T > C (exon 5; p.V200A)
and c.1139+1G > A (intron 7 splice site); patient 2 compound het-
erozygote for c.953A > G (exon 6; p.N291S) and c.1019-3C > A
(intron 6 splice site). Furthermore, in both patients, no pathogenic
mutations in other genes such as APOC2, APOA5, LMF1 and GPIHBP1
have been identiﬁed.
The V200A substitution has been previously identiﬁed in a cohort of
Japanese patients with familial hyperlipidemia [27,28]. According to
the recent pathogenic classiﬁcation of LPL gene variants associated with
LPL deﬁciency, the mutation c.680T > C (exon 5; p.V200A) has been
classiﬁed as a variant of unconﬁrmed pathogenicity being this latter
highly probable [1]. The frequency of the minor allele (C) in the overall
population is 0.003% (gnomAD browser, Broad Institute). Conversely,
concerning the intron 7 splice site mutation, no information regarding
pathogenicity has been found. To our knowledge, this is the ﬁrst time
that this splice site mutation is described. Its frequency in the popula-
tion is lower than 0.001% according to gnomAD browser of Broad
Fig. 2. Circulating LPL levels and LPL activity in
post-heparin plasma from patient 1 and 2.
(A) Western blotting showing circulating levels
of LPL in post-heparin plasma samples from
patient 1 compound heterozygote for
c.680T > C (p.V200A) and c.1139+1G > A
(intron 7 splice site), patient 2 compound het-
erozygote for c.953A > G (p.N291S) and
c.1019-3C > A (intron 6 splice site). Mouse
post-heparin plasma was used as a positive
control (mouse and human LPL amino acidic
sequences show 90% homology). Anti-human
APOA1 antibody was used as a loading control.
Post-h, post-heparin; kDa, kilodalton; LPL, lipoprotein lipase; APOA1, apolipoprotein A1. (B) LPL induced release of radiolabeled oleic acid from triolein was
measured in post-heparin plasma of patient 1 and 2. Mouse post-heparin plasma was used as a positive control. Sodium chloride 1 M (NaCl) was used to inhibit
speciﬁcally LPL activity.
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Institute. Hence, we describe a novel pathogenic LPL splice site muta-
tion leading to virtual absence of LPL activity and protein.
Biochemical analysis of LPL activity was performed in post-heparin
plasma (ex vivo) revealing absence of LPL activity in the sample.
Immunoblot analysis showed only a faint LPL band despite normal
presence of control loading protein (APOA1). Moreover, results in
HEK293T/17 showed a marked reduction in LPL secretion although the
dimerization analysis revealed that there was no diﬀerence compared
to the wild-type.
The c.953A > G mutation (exon 6; p.N291S), found in patient 2 is
considered as “pathogenicity is doubtful”, whereas the second mutation
of the same patient c.1019-3C > A (intron 6 splice site) is considered
as “pathogenic” [1]. The c.953A > G mutation (p.N291S) has been
identiﬁed and described by several authors [29–33].
Reymer et al. found that the N291S mutation has a high frequency
in a cohort of patients with coronary artery disease and it is associated
with high levels of TGs and low levels of HDL cholesterol [29]. How-
ever, the frequency of the minor allele (G) in the overall population is
1.3%. In particular, Reymer and collaborators showed that, in ap-
proximately 1 in 20 males with proven atherosclerosis, the current
variant is associated with signiﬁcantly reduced HDL cholesterol levels
(p=0.001) and resulted in a signiﬁcant decrease in LPL catalytic ac-
tivity (p < 0.0009) [29]. Buscà et al. showed that both the wild-type
and N291S human LPL expressed in COS-1 cells were secreted to the
extracellular medium and presented similar intracellular distribution
patterns consistently with our results. Furthermore, heparin-Sepharose
aﬃnity chromatography assays revealed normal heparin aﬃnity of the
N291S. In addition, both the mutant and the wild type proteins bound
to the surface of human ﬁbroblasts and of un-transfected COS-1 cells
[31].
This mutation has also been described and associated with LPL
deﬁciency by Mailly and colleagues, who investigated a patient with
LPL deﬁciency with a history of acute pancreatitis [32]. In vitro muta-
genesis and homozygous expression studies conﬁrmed that the N291S
substitution is associated with a signiﬁcant reduction in LPL activity.
This patient was also carrying a mutation of the LPL intron 6 splice site
(frequency in the overall population 0.0016%). This mutation was
identiﬁed for the ﬁrst time by Hölzl and co-workers in three families
living in the same geographic area, a secluded valley in Austria [21].
Interestingly, the splice site was found in homozygosity in some pa-
tients and heterozygosity in others. In particular, one patient was a
compound heterozygote carrying the splice site mutation on one allele
and a missense mutation (G188E) on the other allele. The blood sample
of this patient did not show any LPL activity similarly to our compound
heterozygote patient 2. Clearly, mutations of splice site of introns may
have various consequences that cannot be predicted by the primary
Fig. 3. HEK 293T/17 cells transiently trans-
fected with wild type or mutants LPL (V200A
and N291S).
(A) Western blotting analysis of cell lysates
(N=5) shows no reduction in the production of
LPL-V5 tagged mutant forms compared to the
wild type form (mean ± SD); calnexin was used
as loading control. (B) Western blotting analysis
of cell media (N=8) shows a strong reduction
in the secretion of LPL-V5 tagged V200A form,
but not in the secretion of N291S LPL form
(mean ± SD); albumin was used as loading
control. EV: empty vector; WT: wild type; CNX:
calnexin; ALB: albumin. p value was calculated
by Mann Whitney test, (p=0.008).
Fig. 4. LPL activity is absent in the media of HEK 293T/17 cells transfected
with V200A and N291S LPL.
LPL induced release of radiolabeled oleic acid from triolein was measured in
cell media of HEK 293T/17 cells transiently transfected with wild type, V200A
or N291S LPL. Wild-type (WT) LPL medium was used as a positive control.
Sodium chloride 1M (NaCl) was used to inhibit speciﬁcally LPL activity.
Fig. 5. A non-denaturing Western blot analysis of LPL dimerization in post-
heparin plasma and HEK293 T/17 conditioned media.
(A) Non-denaturing Western blotting showing circulating levels of LPL in post-
heparin plasma samples from patient 1 compound heterozygote for
c.680T > C (p.V200A) and c.1139+1G > A (intron 7 splice site), patient 2
compound heterozygote for c.953A > G (p.N291S) and c.1019-3C > A (in-
tron 6 splice site). Mouse post-heparin plasma was used as a positive control.
(B) Non-denaturing Western blotting analysis of cell media shows no diﬀerence
in dimerization of LPL-V5 tagged mutant forms compared to the wild type form.
EV: empty vector; WT: wild type. Ponceau was used as loading control.
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sequence alone [21]. Functional analysis of LPL activity was performed
on post-heparin plasma (ex vivo), revealing absence of LPL activity in
the sample. Immunoblot analysis showed only a faint LPL band despite
normal presence of control protein (APOA1). Moreover, in vitro ex-
periments showed that the N291S, per se, does not aﬀect protein
synthesis and secretion although strongly aﬀecting LPL enzymatic ac-
tivity. Furthermore, compared to the wild-type protein, the dimer for-
mation was not aﬀected by the mutation.
Consistently with our ﬁndings, most of the deleterious missense
mutations involve exons 5 and 6. Missense mutations in these exons
have been suggested to cause LPL protein homo-dimer instability and,
thus, LPL deﬁciency [34]. More speciﬁcally, LPL protein is organized
into two distinct structural domains, N-terminal (residues 1–312) and
C-terminal (residues 313–448) (Fig. 6). The lid structure (residues
216–239) that covers the catalytic site is located in the N-domain.
Exons 1–4 and exons 5–6 make up the upper and lower parts of the N-
domain, respectively, whereas exons 7–9 make up the C-domain. Raz-
zaghi et al. found that more than 60% of the point mutations occurred
in exons 5 and 6 contributing to the catalytic domain and the lid
structure [35].
In general, lipoprotein lipase genes cluster in exons 5 and 6 leading
to mutant proteins unable to achieve or maintain normal dimer con-
formation, thus, becoming inactive [7,34,36]. On the other hand, sub-
jects with insertion/deletion, nonsense or splice site mutations usually
are unable to produce the LPL protein and, thus, are deleterious mu-
tations [1].
For fully enzymatic activity, LPL requires some important cofactors
such as apolipoprotein CeII and A-V (APO-CII, APO-AV) [37,38], gly-
cosylphosphatidylinositol-anchored high density lipoprotein binding
protein 1 (GPIHBP1) [25], lipase maturation factor 1 (LMF1) [39].
Although missense mutations may aﬀect the interaction with these
cofactors, in this work we did not test whether V200A or N291S mu-
tations aﬀected any interactions with LPL cofactors. This can be listed
as limitation of our study.
In our patient, the heterozygous intron 6 splice site mutation
c.1019-3C > A at least in conjunction with the N291S mutation
clinically acts like a dominant negative variant.
Overall, this information clearly explains the severe phenotype in
compound heterozygous patients due to the additional eﬀect of both the
mutations.
The identiﬁcation of LPL mass in blood samples of patients aﬀected
by type I hypertriglyceridemia is a crucial information for the treatment
of those patients. Treatment with alipogene tiparvovec in patients with
no LPL mass may be not successful due to immune response to the in-
jected functional LPL protein; however, Glybera (alipogene tiparvovec)
is being withdrawn due to a cost-eﬀectiveness analysis [20].
In conclusion, we have fully characterized two known missense
mutations (p.V200A and p.N291S) by ex vivo and in vitro experiments
and tested the additional eﬀect of two splice site mutations by ex vivo
experiments. The splice site mutation c.1019-3C > A (intron 6) has
been already described while the c.1139+1G > A (intron 7) is iden-
tiﬁed and described in this work for the ﬁrst time.
Conﬂict of interest
SR has been consulting for Chiesi Farmaceutici Group, Amgen,
Sanoﬁ, Novonordisk, Akcea therapeutics, Genzyme and Astra Zeneca in
the last 5 years.
Authors contributions
ER performed genetic analysis. TMS performed clinical diagnosis.
PP designed the study and performed the experiments. MB performed
the experiments. All authors contributed to the manuscript preparation
and interpretation of data.
Financial support
This work was supported by the Swedish Research Council
[Vetenskapsrådet (VR), 2016-01527], the Swedish Heart-Lung
Foundation [20120533], the Swedish state under the agreement be-
tween the Swedish government and the county councils, the ALF-
agreement (SU 2018-04276), the Novonordisk Foundation Grant for
Excellence in Endocrinology [Excellence Project, 9321-430], the
Swedish Diabetes Foundation [DIA 2017-205], a research grant from
AstraZeneca [Echo Project, 10033852], Wallenberg Academy Fellows
from the Knut and Alice Wallenberg Foundation [KAW 2017.0203]
(SR).
References
[1] R. Rodrigues, M. Artieda, D. Tejedor, et al., Pathogenic classiﬁcation of LPL gene
variants reported to be associated with LPL deﬁciency, J Clin Lipidol 10 (2016)
394–409.
[2] D.J. Rader, M. Jaye, Endothelial lipase: a new member of the triglyceride lipase
gene family, Curr. Opin. Lipidol. 11 (2000) 141–147.
[3] M. Merkel, R.H. Eckel, I.J. Goldberg, Lipoprotein lipase: genetics, lipid uptake, and
regulation, J. Lipid Res. 43 (2002) 1997–2006.
[4] Y. Li, P.P. He, D.W. Zhang, et al., Lipoprotein lipase: from gene to atherosclerosis,
Atherosclerosis 237 (2014) 597–608.
[5] K.J. Williams, Molecular processes that handle – and mishandle – dietary lipids, J.
Clin. Invest. 118 (2008) 3247–3259.
[6] P. Tornvall, G. Olivecrona, F. Karpe, et al., Lipoprotein lipase mass and activity in
plasma and their increase after heparin are separate parameters with diﬀerent re-
lations to plasma lipoproteins, Arterioscler. Thromb. Vasc. Biol. 15 (1995)
1086–1093.
[7] B. Gilbert, M. Rouis, S. Griglio, et al., Lipoprotein lipase (LPL) deﬁciency: a new
patient homozygote for the preponderant mutation Gly188Glu in the human LPL
gene and review of reported mutations: 75 % are clustered in exons 5 and 6, Ann.
Genet. 44 (2001) 25–32.
[8] D. Pasalić, Z. Jurcić, G. Stipancić, et al., Missense mutation W86R in exon 3 of the
lipoprotein lipase gene in a boy with chylomicronemia, Clin. Chim. Acta 343 (2004)
179–184.
Fig. 6. Homology structural models of human
wild-type LPL, V200A and N291S mutants.
Ribbon diagram viewing the monomer of LPL
organized into two distinct structural domains,
amino terminal (residues 1–312) and carboxy
terminal (residues 313–448). The model was
obtained using the crystallographic structure of
the human pancreatic lipase-related protein 1 as
template. The calculated models were visualized
by Swiss PDB Viewer 4.1.0. (A) The LPL model
was mutated at position 200 by substituting
valine (V), a non-polar aliphatic residue, for
alanine (A), another non-polar aliphatic residue.
(B) The same procedure was applied to the
N291S mutation, substituting asparagine (N), an
uncharged polar residue, at position 291 for
serine (S), another uncharged polar residue.
M. Botta et al. Atherosclerosis 282 (2019) 45–51
50
[9] P.D. Stenson, E.V. Ball, M. Mort, et al., Human gene mutation database (HGMD):
2003 update, Hum. Mutat. 21 (2003) 577–581.
[10] V. Murthy, P. Julien, C. Gagne, Molecular pathobiology of the human lipoprotein
lipase gene, Pharmacol. Ther. 70 (1996) 101–135.
[11] S. Santamarina-Fojo, The familial chylomicronemia syndrome, Endocrinol Metab.
Clin. N. Am. 27 (1998) 551–567 (viii).
[12] J.D. Brunzell, Familial lipoprotein lipase deﬁciency, in: R.A. Pagon, M. A,
H.H. Ardinger, S.E. Wallace, A. Amemiya, L.J.H. Bean, T.D. Bird, C.T. Fong,
H.C. Meﬀord, R.J.H. Smith, K. Stephens (Eds.), GeneReviews® [Internet]. Seattle
(WA), University of Washington, Seattle, 20141993-2015. and 24]., O. u. A. (eds).
[13] A. Caddeo, R.M. Mancina, C. Pirazzi, et al., Molecular analysis of three known and
one novel LPL variants in patients with type I hyperlipoproteinemia, Nutr. Metabol.
Cardiovasc. Dis. 28 (2018) 158–164.
[14] P. Pingitore, S.M. Lepore, C. Pirazzi, et al., Identiﬁcation and characterization of
two novel mutations in the LPL gene causing type I hyperlipoproteinemia, J Clin
Lipidol 10 (2016) 816–823.
[15] M. Rehmanjan, Is plasmapheresis the optimal treatment option for acute pancrea-
titis secondary to hypertriglyceridemia? A systematic review, Acad. Market. Stud. J.
4 (2013) 19.
[16] P. Nasa, G. Alexander, A. Kulkarni, et al., Early plasmapheresis in patients with
severe hypertriglyceridemia induced acute pancreatitis, Indian J. Crit. Care Med. 19
(2015) 487–489.
[17] U. Kassner, T. Hollstein, T. Grenkowitz, et al., Gene therapy in lipoprotein lipase
deﬁciency: case report on the ﬁrst patient treated with alipogene tiparvovec under
daily practice conditions, Hum. Gene Ther. 29 (2018) 520–527.
[18] D. Melchiorri, L. Pani, P. Gasparini, et al., Regulatory evaluation of Glybera in
Europe - two committees, one mission, Nat. Rev. Drug Discov. 12 (2013) 719.
[19] A.S. Wierzbicki, A. Viljoen, Alipogene tiparvovec: gene therapy for lipoprotein li-
pase deﬁciency, Expert Opin. Biol. Ther. 13 (2013) 7–10.
[20] M. Senior, After Glybera's withdrawal, what's next for gene therapy? Nat.
Biotechnol. 35 (2017) 491–492.
[21] B. Hölzl, R. Huber, B. Paulweber, et al., Lipoprotein lipase deﬁciency due to a 3'
splice site mutation in intron 6 of the lipoprotein lipase gene, J. Lipid Res. 35 (1994)
2161–2169.
[22] S. Schmaldienst, S. Banyai, T.M. Stulnig, et al., Prospective randomised cross-over
comparison of three LDL-apheresis systems in statin pretreated patients with fa-
milial hypercholesterolaemia, Atherosclerosis 151 (2000) 493–499.
[23] S. Richards, N. Aziz, S. Bale, et al., Standards and guidelines for the interpretation of
sequence variants: a joint consensus recommendation of the American College of
medical genetics and genomics and the association for molecular Pathology, Genet.
Med. 17 (2015) 405–424.
[24] R.A. Hegele, H.N. Ginsberg, M.J. Chapman, et al., The polygenic nature of hyper-
triglyceridaemia: implications for deﬁnition, diagnosis, and management, Lancet
Diabetes Endocrinol 2 (2014) 655–666.
[25] A.P. Beigneux, B.S. Davies, P. Gin, et al., Glycosylphosphatidylinositol-anchored
high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic
processing of chylomicrons, Cell Metabol. 5 (2007) 279–291.
[26] E. Steinhagen-Thiessen, E. Stroes, H. Soran, et al., The role of registries in rare
genetic lipid disorders: review and introduction of the ﬁrst global registry in lipo-
protein lipase deﬁciency, Atherosclerosis 262 (2017) 146–153.
[27] T. Maruyama, S. Yamashita, Y. Matsuzawa, et al., Mutations in Japanese subjects
with primary hyperlipidemia–results from the research committee of the ministry of
health and welfare of Japan since 1996–, J. Atherosclerosis Thromb. 11 (2004)
131–145.
[28] A. Takagi, Y. Ikeda, M. Tsushima, et al., Molecular and environmental bases of
primary type IV hyperlipoproteinemia: heterozygous lipoprotein lipase deﬁciency
as a causal genetic disorder, Atherosclerosis 134 (1997) 27–28 In, 1.P.54.
[29] P.W. Reymer, E. Gagné, B.E. Groenemeyer, et al., A lipoprotein lipase mutation
(Asn291Ser) is associated with reduced HDL cholesterol levels in premature
atherosclerosis, Nat. Genet. 10 (1995) 28–34.
[30] M.E. Wittekoek, S.N. Pimstone, P.W. Reymer, et al., A common mutation in the
lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for car-
diovascular disease in patients with familial hypercholesterolemia, Circulation 97
(1998) 729–735.
[31] R. Buscà, J. Peinado, E. Vilella, et al., The mutant Asn291–>Ser human lipopro-
tein lipase is associated with reduced catalytic activity and does not inﬂuence
binding to heparin, FEBS Lett. 367 (1995) 257–262.
[32] F. Mailly, J. Palmen, D.P. Muller, et al., Familial lipoprotein lipase (LPL) deﬁciency:
a catalogue of LPL gene mutations identiﬁed in 20 patients from the UK, Sweden,
and Italy, Hum. Mutat. 10 (1997) 465–473.
[33] M. Overgaard, C.L. Brasen, D. Svaneby, et al., Familial lipoprotein lipase deﬁciency:
a case of compound heterozygosity of a novel duplication (R44Kfs*4) and a
common mutation (N291S) in the lipoprotein lipase gene, Ann. Clin. Biochem. 50
(2013) 374–379.
[34] J. Peterson, A.F. Ayyobi, Y. Ma, et al., Structural and functional consequences of
missense mutations in exon 5 of the lipoprotein lipase gene, J. Lipid Res. 43 (2002)
398–406.
[35] H. Razzaghi, B.W. Day, R.J. McClure, et al., Structure-function analysis of D9N and
N291S mutations in human lipoprotein lipase using molecular modelling, J. Mol.
Graph. Model. 19 (2001) 487–494 587-490.
[36] P. Blackett, J. Tryggestad, S. Krishnan, et al., Lipoprotein abnormalities in com-
pound heterozygous lipoprotein lipase deﬁciency after treatment with a low-fat diet
and orlistat, J Clin Lipidol 7 (2013) 132–139.
[37] S.S. Fojo, A.F. Stalenhoef, K. Marr, et al., A deletion mutation in the ApoC-II gene
(ApoC-II Nijmegen) of a patient with a deﬁciency of apolipoprotein C-II, J. Biol.
Chem. 263 (1988) 17913–17916.
[38] S. Calandra, C. Priore Oliva, P. Tarugi, et al., APOA5 and triglyceride metabolism,
lesson from human APOA5 deﬁciency, Curr. Opin. Lipidol. 17 (2006) 122–127.
[39] M. Péterfy, O. Ben-Zeev, H.Z. Mao, et al., Mutations in LMF1 cause combined lipase
deﬁciency and severe hypertriglyceridemia, Nat. Genet. 39 (2007) 1483–1487.
M. Botta et al. Atherosclerosis 282 (2019) 45–51
51
